Drug Trial Radar · NCT00127205
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
Last checked: Nov 19, 2026Latest source record: Jul 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,097
Actual
Start
Jul 2005
Primary completion
Dec 2017
Study completion Mar 29, 2021
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; NSABP Foundation Inc; Cancer and Leukemia Group B; NCIC Clinical Trials Group
- First posted
- Aug 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Conditions
- Breast Cancer
Interventions
clodronate disodiumDrug
Given orally
ibandronate sodiumDrug
Given orally
zoledronic acidDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free SurvivalTime frame: Disease assessments are completed every 6 months for 5 years then annually for 5 years or until death or recurrence
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.